Flexural circumscribed juvenile pityriasis rubra pilaris: An unusual presentation

Zeeshan,; Jha, Abhijeet Kumar; Arfeen, Noorussaba; Chaudhary, RK P

doi:10.4103/ijd.ijd_340_17

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 3 studies describing an unusual distribution of PRP lesions were: cyclical lesions on inguinal and scrotal regions (n = 1), persistent lesions on the antecubital and popliteal areas (n = 1), and widespread eruption after a chronic localized disease suggestive of mixed type III/IV disease (n = 1). [18][19][20] Two case reports outlined typical clinical and dermoscopic findings in PRP patients.…”

Section: Clinical Manifestations and Laboratory Findingsmentioning

confidence: 99%

Updates on Pityriasis Rubra Pilaris: A Scoping Review

Zhou,

Al Muqrin,

Abu-Hilal

2024

J Cutan Med Surg

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare, inflammatory papulosquamous skin disease with unknown exact etiology. Historically, PRP has been challenging to diagnose, especially during the acute phase, and to treat, due to its unclear pathogenesis. To better inform clinical practice, a literature review was conducted employing a broad search strategy to capture PRP-related published studies between January 1, 2012 to October 31, 2022. Two hundred twenty-one studies were identified, which were categorized into 9 themes: (1) potential causes and triggering factors, (2) comorbidities, (3) diagnostic difficulties, (4) genetics, (5) clinical manifestations and laboratory values, (6) treatment, (7) treatment-related adverse events, (8) quality of life, and (9) other. COVID-19 infection, COVID-19 vaccination, and malignancy were the most commonly reported potential triggering factors. Misdiagnosis is very common during the early acute stages. Pathogenesis and genetic studies have further implicated caspase recruitment domain family member 14 (CARD14) mutations in the development of familial PRP (Type V) and have underlined the overlap between psoriasis and PRP. To date, there are currently no specific and validated scoring systems or tools to assess the severity of PRP. While large, randomized trials are still lacking, biologic agents remain the most effective therapy.

show abstract

Section: Clinical Manifestations and Laboratory Findingsmentioning

confidence: 99%